Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of in vivo-derived CMS4-met cells and the in vitro-derived CMS4.sel cells using CMS4 cells as a reference sample


ABSTRACT: The CMS4 sarcoma, kindly provided by A. DeLeo (University of Pittsburgh, Pittsburgh, PA), is a solid tumor of BALB/c (H-2d) origin, which grows aggressively in naive, syngeneic hosts following a s.c. transplant. Although the parental tumor cell line forms few metastatic foci in the lungs following i.v. administration, a highly metastatic subline, termed CMS4-met, was established from lung digests of those mice as described (Ryan MH, Bristol JA, McDuffie E, Abrams SI. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 2001;167:4286-92). The CMS4.sel subline was selected from the parental line in vitro following six successive passages in the presence of anti-Fas stimuli as described (Liu K, Abrams SI. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 2003;170:5973-80).
In this experiment we compare the gene expression patterns of the in vivo-derived CMS4-met cells and the in vitro-derived CMS4.sel cells using CMS4 cells as a reference sample.

ORGANISM(S): Mus musculus

SUBMITTER: Kebin Liu 

PROVIDER: E-MEXP-286 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.

Liu Kebin K   Caldwell Sheila A SA   Abrams Scott I SI  

Cancer research 20050501 10


Antitumor responses can be induced in patients via active or adoptive immunotherapy, yet complete tumor eradication occurs infrequently. This paradox in tumor immunology led us to address two questions: (a) Does an antitumor response, which is intended to destroy the aberrant target population, also at the same time select for aggressive tumor variants (ATV) in vivo? (b) If this process does occur, what is the contribution of the perforin- or Fas-mediated effector mechanism in the immune selecti  ...[more]

Similar Datasets

2005-05-08 | E-MEXP-288 | biostudies-arrayexpress
2005-05-08 | E-MEXP-287 | biostudies-arrayexpress
2005-03-10 | E-MEXP-277 | biostudies-arrayexpress
2021-02-07 | E-MTAB-6512 | biostudies-arrayexpress
2010-06-08 | E-GEOD-16554 | biostudies-arrayexpress
| PRJDB7601 | ENA
2009-05-06 | GSE14244 | GEO
2018-12-31 | GSE99507 | GEO
2016-03-03 | E-GEOD-62636 | biostudies-arrayexpress
2014-01-17 | GSE54175 | GEO